Perturbation of cell signalling through inhibition of kinase enzymes has delivered nearly 30 approved medicines to date. The seventh SCI/RSC symposium on kinase inhibitor design will feature several highly pertinent themes including new approaches and technologies to modulate and measure kinase function as well as diverse medicinal chemistry case studies. The symposium will also draw on the lessons from history to provide insight into the future direction of the field.
In addition to medicinal discovery scientists wishing to further their knowledge of kinases, the meeting will also be of great value to the wider drug discovery community. It will provide transferable lessons and insight into how new approaches and technologies are being applied in a successful and maturing field of research.
Day 1 - Sunday 15th May
- Welcome drinks reception Jurys Inn Nottingham Hotel
Day 2 - Monday 16th May
- Registration and refreshments
- Opening remarks
- Kinase drug discovery: past, present, and future Mark Bunnage, Pfizer, USA
- Identifying high quality, potent and selective inhibitors of ATM kinase: discovery of AZD0156 Kurt Pike, AstraZeneca, UK
- Refreshment break
- Kinase identification of proximal substrates (KIPS): a novel chemical genetics approach for kinase substrate identification Jon Roffey, Cancer Research Technology, UK
- Roger Griffin Memorial Lecture: Development of potent inhibitors of the DNA-dependent protein kinase (DNA-PK) Celine Cano, Northern Institute for Cancer Research, UK
- Lunch and exhibition
- The ups and downs of IRE1 kinase-ribonuclease allosteric ligands John Caldwell, The Institute of Cancer Research, UK
- Fragment molecular orbital method in kinase ‘real-life’ structure-based drug design Ewa Chudyk, Evotec (UK) Ltd, UK
- Protein degradation using PROTACs as a novel approach to silence kinase function John Harling, GlaxoSmithKline, UK
- Refreshment break
- Discovery and optimisation of 2,3-dihydroimidazo[1,2-c]quinazolines as PI3K inhibitors Julien Lefranc, Bayer Pharma AG, Germany
- Discovery of the EGFR-T790M mutant inhibitor PF-06747775; irreversible inhibitor design and proteomic profile Simon Planken, Pfizer, USA
- Flash poster presentations
- Networking reception, exhibition and posters
- Transfer by shuttle bus to conference dinner
- Conference dinner The Riverbank Bar & Kitchen
Day 3 - Tuesday 17th May
- A retrospective of kinase drug discovery at AstraZeneca: the critical role of institutional medicinal chemistry knowledge in generating new leads Jason Kettle, AstraZeneca, UK
- Identification of highly potent and mono-selective RIP1 kinase inhibitors targeting a unique allosteric pocket Phil Harris, GlaxoSmithKline, USA
- Refreshment break
- Poster prize presentation
- PDGFR inhibitors suitable for inhalation as a treatment for lung remodeling in pulmoanary arterial hypertension (PAH) Duncan Shaw, Novartis, USA
- Discovery of non-covalent BTK inhibitors for the treatment of rheumatoid arthritis and lupus James Crawford, Genentech, USA
- Interactive session
- Lunch and exhibition
- Filgotinib: a selective JAK1 inhibitor Oscar Mammoliti, Galapagos, Belgium
- Design strategies for the development of selective kinase inhibitors Stefan Knapp, Johann Wolfgang Goethe-University, Germany
- Concluding remarks
Venue and Contact
Early bird fees before Friday 01 April 2016
GB£240 . . . . . . . . . . . . . . . . . SCI/RSC Member
GB£125 . . . . . . . . . . . . . . . . . SCI/RSC Student Member
GB£145 . . . . . . .. . . . . . . . . . .SCI/RSC Subsidised Member*
GB£290 . . . . . . . . . . . . . . . . . Non-Member
Standard fees after Friday 01 April 2016
GB£290 . . . . . . . . . . . . . . . . . SCI/RSC Member
GB£150 . . . . . . . . . . . . . . . . . SCI/RSC Student Member
GB£175 . . . . . . . . . . . . . . . . . SCI/RSC Subsidised Member*
GB£350 . . . . . . . . . . . . . . . . . Non-Member
* Criteria applies.
Become an SCI Member and save on this and future events
See Membership Options
Sign up as an Event Member to join this event. SCI Full or Student Members receive discounts on event registrations
SCI Members attending this meeting are able to claim CPD points.
An exhibition will run alongside the conference during refreshment breaks, for companies and related organisations who may wish to exhibit. For further information and prices please email firstname.lastname@example.org.
BioCity is located on Pennyfoot Street, Nottingham and can be accessed easily from both the North and the South of England via the M1. For detailed directions please click here. Please note: there is no parking available at BioCity, please click here for local car parks within a 10 minute walk from the venue.
Nottingham train station is situated a 10–15 minute walk from BioCity (download directions here) and the closest international airport to Nottingham is East Midlands Airport, 13 miles from the conference venue. This is approximately a 30 minute taxi ride to the conference venue and Jurys Inn Nottingham hotel.
An accommodation package is available for this event. This package consists of two nights at Jurys Inn Nottingham (Sunday 15 and Monday 16 May) at a special rate of £90 (breakfast included). SCI will organise the administration of your booking with Jurys Inn Nottingham.
The hotel is situated approximately 5 minutes’ walk from Nottingham train station and 5–10 minutes from the event venue at BioCity (download directions here). If you are driving to the hotel, click here for Jurys Inn’s car parking information and prices.
The Organising Committee are hosting a welcome drinks reception on Sunday 15 May at Jurys Inn Nottingham, in the hotel’s restaurant, from 21:00. Please indicate if you intend to join us at the drinks reception when making your booking.
Please note: there will be no food included at the drinks reception, a list of local restaurants can be found here.
A buffet dinner will be held at The Riverbank Bar and Kitchen on Monday 16 May. A shuttle bus service will be provided to transfer all delegates from BioCity to the restaurant at 19:00 with dinner being served at 19:30.
Please note: the conference dinner is included in the delegate registration fee.